Business Wire

Energy Impact Partners Backs Greentech Zolar, Increases Series B to 35 Million

16.3.2021 17:15:00 EET | Business Wire | Press release

Share

The Berlin-based Greentech start-up Zolar receives a new investment and adds 10 million euro to the ongoing Series B funding round, raising the total investment of this series to 35 million euro. The new investment is lead by Energy Impact Partners, the biggest investor in the energy sector with offices in the USA and Europe headed by its managing partner Matthias Dill. Existing investors continue to support Zolar in the Series B. With the additional resources, the start-up sets the course for the expansion as a next generation green energy company, focusing on sustainable energy production and integral use of solar energy in private households. Zolar as a consumer brand, is placing customers at the center of energy production, and is driven by its mission of climate protection as a top business priority.

Energy provider of the future– The Next Generation Green Energy Company

The start-up defines five quality criteria, which represent the next generation of energy companies: decentralized renewable energy systems, green and affordable energy, customer centricity, significant reduction in customers’ carbon footprint, with an ultimate goal of carbon neutrality, as well as electrification and smart energy management. By installing a solar system on their own roof, customers are enabled to secure and allocate the main energy requirements of the household. Essential to this is the combination of electric mobility and solar energy, as well as the usage of self-generated power stored in residential batteries. The need for green and sustainably produced energy is also evident, due to rapidly increasing demands from customers. Zolar responds to this trend and offers homeowners an alternative to traditional energy companies, who continue to rely on fossil fuels.

“We find ourselves at the dawn of the solar age” explains Alex Melzer, CEO and co-founder of Zolar. “The solar sector proved to be very stable during the Covid-19 pandemic. In the past year, we have been able to grow our revenue significantly, and in 2021, we are targeting to triple installations across Germany. With the fresh 10 million, we are taking the company to the next level and The investment of Energy Impact Partners shows that investors recognise the relevance of regenerative energy. In doing so, they support us to grow quicker, accelerate revenue growth while at the same time having a positive impact on climate protection. Because ultimately what drives us all, is a livable future for all humans”, continued Melzer.

Private households become energy suppliers

In order for every household to become its own energy supplier, Zolar relies on technological platform solutions across the whole value chain. With full service digital concept, beginning with the Zolar Online Configurator, from a holistic customer journey to roof installation via the partner platform Zolar Project Center. The company intends to establish itself as a leading customer brand in the energy sector and is planning an expansion of the core business. In keeping with the requirement of an electrified household, the product portfolio will facilitate an integration of energy production, power storage and mobility.

“Zolar is one of the fastest growing energy start-ups in Germany”, added Matthias Dill, Managing Partner of Energy Impact Partners. “At Energy Impact Partners we closely monitor the transformation of the energy sector and with this investment we intend to provide ongoing support for Zolar’s goal – to become the energy provider of the future. The combination of technological state-of-the-art platforms, customer success and climate protection is a clear formula for success for us” continued Dill.

About Zolar

The Greentech start-up Zolar offers fixed-priced photovoltaic systems, which home owners can plan, compare and commission online, according to their needs. With the help of the in-house developed Zolar Online Configurator, homeowners have the possibility to adjust the components of their PV system according to their wishes, and along with this, receive an individual consultation from solar experts. Zolar’s wide network of local partner businesses carries out the installation on-site. The Berlin start-up employs around 150 employees across Germany and pursues the vision, to install solar panelling on every roof in the world, granting private households greater independence from energy supply systems. The gearing of energy production, energy storage and mobility enables the customer to design an electrified and smart household. As a next green energy company, Zolar empowers its customers to become energy suppliers within its own four walls, to neutralize their carbon footprint and to make an impact towards climate protection.

More information at: http://www.zolar.de

About Energy Impact Partners

Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, and Cologne.

For more information on EIP, please visit: www.energyimpactpartners.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact
Lina Wölm
VP Marketing & Communications
Phone: +49 30 398 218 443
Email: lina.woelm@zolar.de
Website: http://www.zolar.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye